Digest Network Come funziona
Network
/
Società
Br
Non verificato

Bristol Myers Squibb

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

107 comunicati stampa

Guarda tutti i comunicati
05/12/2025
Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
03/12/2025
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
01/12/2025
Eventi
Fiere
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Bristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation Portfolio
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
26/11/2025
Eventi
Biotecnologia
Farmaceutica
Salute
Bristol Myers Squibb to Participate in Citi’s 2025 Global Healthcare Conference
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
24/11/2025
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
24/11/2025
Web e Social Network
Eventi
Biotecnologia
Farmaceutica
Salute
Bristol Myers Squibb to Host Hematology-Focused Investor Event
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
18/11/2025
Finanza
Biotecnologia
Farmaceutica
Salute
Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
18/11/2025
Biotecnologia
Finanza
Salute
Associazioni/Professionisti
Farmaceutica
Titoli e azioni
Bristol Myers Squibb Announces Early Participation Results, Amendment and Early Settlement of Tender Offers
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
14/11/2025
Mercato del lavoro
Industria
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Update on Phase 3 Librexia ACS Trial
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
05/11/2025
Biotecnologia
Farmaceutica
Salute
Oncologia
Titoli e azioni
Bristol Myers Squibb Prices €5 Billion of Senior Unsecured Notes
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0